Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 7/20 | 0.50 |
| ▸ | DRD5 | P21918 | 7/20 | 0.50 |
| ▸ | DRD2 | P14416 | 7/20 | 0.50 |
| ▸ | DRD3 | P35462 | 7/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444147 | 0.93 | DRD2 (0.47) | DRD1DRD5DRD2DRD3CHRNA7 | |
| SCHEMBL8419347 | 0.89 | DRD1 (0.48) | DRD1DRD5DRD2DRD3CHRNA7 | |
| SCHEMBL1550649 | 0.89 | DRD1 (0.53) | DRD1DRD5DRD2DRD3CHRNA7 | |
| SCHEMBL586334 | 0.84 | DRD2 (0.47) | DRD1DRD5DRD2DRD3CHRNA7 | |
| SCHEMBL2302727 | 0.80 | PPARG (0.40) | — | |
| SCHEMBL2607471 | 0.78 | DRD1 (0.62) | DRD1DRD5DRD2DRD3CHRNA7 | |
| SCHEMBL3130115 | 0.77 | CHRNB2 (0.37) | DRD1CHRNA7 | |
| SCHEMBL2302335 | 0.77 | GPR3 (0.39) | — | |
| SCHEMBL2097306 | 0.76 | PDE4A (0.42) | — | |
| SCHEMBL31121180 | 0.75 | DRD1 (0.47) | DRD1DRD5DRD2DRD3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | claimed |
| EP-2382012-A2 | PHARMACEUTICAL COMPOUNDS | Bial-Portela & CA, S.A. (PT) | 2011-11-02 | — | — | EP | claimed |
| WO-2010074588-A2 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2010-07-01 | — | — | WO | claimed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| EP-0614893-B1 | Benzoxazine derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1998-05-27 | — | — | EP | claimed |
| US-5447928-A | Antiischemic agents and nervous system disorders | SYNTHELABO (FR) | 1995-09-05 | — | — | US | claimed |
| US-11771695-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11746091-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2022-08-04 | — | — | US | disclosed |
| CN-109970708-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11214548-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| US-5447928-A | Antiischemic agents and nervous system disorders | SYNTHELABO (FR) | 1995-09-05 | — | — | US | disclosed |
| US-5447928-A | Antiischemic agents and nervous system disorders | SYNTHELABO (FR) | 1995-09-05 | — | — | US | disclosed |
| CN-1106405-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating | THOMAE GMBH DR K (DE) | 1995-08-09 | — | — | CN | disclosed |
| EP-0645390-A1 | Trisubstituted pyrimido 5,4-d pyrimidines for modulating multidrug resistance, drugs containing these compounds and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1995-03-29 | — | — | EP | disclosed |
| EP-0614893-A1 | Benzoazine derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1994-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | DRD1 1465/4885DRD5 1393/4885DRD2 1476/4885 |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | DRD1 1830/4885DRD5 1406/4885DRD2 1602/4885 |
| US-11746091-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | DRD1 1465/4885DRD5 1393/4885DRD2 1476/4885 |
| US-11214548-B2 | Cannabinoid receptor modulators | CNR1, CNR2, TRPV1 | DRD1 1465/4885DRD5 1393/4885DRD2 1476/4885 |
| US-20220241274-A1 | CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | DRD1 1041/4885DRD5 1417/4885DRD2 669/4885 |
| US-11771695-B2 | Cannabinoid receptor modulators | CNR2, CNR1, OPRL1 | DRD1 1041/4885DRD5 1417/4885DRD2 669/4885 |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, TRPV1 | DRD1 1465/4885DRD5 1393/4885DRD2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.